Long Regulatory Saga for Intercept Pharma Liver Drug Ends a Decade After Speedy FDA Approval

Intercept Pharmaceuticals is voluntarily withdrawing from the market Ocaliva, a drug for the rare liver disease primary biliary cholangitis. While Ocaliva became an important new treatment option when it won accelerated FDA approval in 2016, PBC patients now have new FDA-approved medicines from Ipsen and Gilead Sciences that don’t pose the same safety risks. The…

Read More

Collaborative Networks Become Popular Lifeline for Rural Hospitals

BOWMAN, N.D. — Independent rural hospitals are increasingly forming collaborative groups to share resources and combine bargaining power with the goal of saving money and improving patient care.  The networks, which have cropped up in several states in recent years, offer small-town hospitals an alternative to selling to large hospital systems and forfeiting local autonomy. …

Read More